Secukinumab and ixekizumab in psoriasis: Considerable added benefit for certain patients

There were notably more remissions with Secukinumab and ixekizumab than under the comparator therapies for psoriasis. In future, the analysis of symptoms should not be limited to improvements at one time point.

from Top Health News – ScienceDaily http://bit.ly/2rGQreZ
from Tumblr http://bit.ly/2qQkNfV